What now in HCV? Video and white paper
This article was originally published in Scrip
Executive Summary
The euphoria-inducing near-100% cure rates seen with the new wave of hepatitis C therapies at the European Association for the Study of the Liver (EASL) International Liver Congress in London from 9-13 April have been a highlight of the year, and, some would say, the decade so far. But will the devil be in the detail, and how will the market play out when there are several companies all limbering up to launch highly effective treatments following Gilead Sciences' early lead with Sovaldi (sofosbuvir)?
You may also be interested in...
Gaming Whiz Brings AI Smarts To Drug Discovery
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
The Top 10 Best-Selling Drugs of 2019
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Interview: Why Biotech Companies Should Be Confident About Deals Despite Coronavirus
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
Need a specific report? 1000+ reports available
Buy Reports